12 feb: Opjustering af forventning til årets resultat efter skat på baggr..
13 feb: Indre værdi af SmallCap Danmark A/S er opgjort til 20,6 kr. pr. a..
12-02-2019 10:31:07

Update: Coloplast continues to expand its SenSura® Mio ostomy range with the new, innovative, first-of-its-kind SenSura® Mio Convex Flip ostomy product.

Designed specifically for the outward body shapes – and the first of its kind in the ostomy market – the new SenSura® Mio Convex Flip is now available in the United States.

All bodies are different, and it is a challenge to create products to fit individual bodies. The SenSura Mio ostomy care portfolio is intended to meet the differing needs of ostomates through its BodyFit Technology®. Flat and convex barriers are common, which the SenSura Mio offers a solution for.

SenSura Mio Convex Flip is a new solution for people with an outward body profile and is the first ostomy appliance designed specifically for those that are overweight, obese, or have parastomal bulges or hernias.

“With the addition of SenSura® Mio Convex Flip, we continue to build out our ostomy SenSura® Mio portfolio to meet more people’s needs. It is difficult to make a great fit for people with outward body profiles, but the curved, star-shaped barrier can do just that. We are confident that this will make a big difference to our users and give Coloplast a strong competitive edge,” says CEO Kristian Villumsen, Coloplast.

Committed to improving outcomes via quality products and life-long patient support

Ostomy care is the 2nd leading cause of 30-day readmission rates in the United States. Coloplast® Care, a comprehensive patient support program, provides patients with individualized support, education, and tools via a patient-focused advisor. The program has been shown to reduce 30-day readmission rates by 30 percent and ER visits by 45 percent.

“SenSura® Mio Convex Flip provides a new option for those living with an ostomy. By offering a new innovative product that supports the needs of more users, combined with the Coloplast Care program, we not only impact the quality of life for people living with a stoma – we also make a positive effect on health outcomes,” says Senior Vice President Manu Varma, Chronic Care in North America.

Coloplast is the global market leader in ostomy care products, holding 35-40% of the market. Ostomy care products experienced 8% organic growth in 2018, with double-digit growth coming from the United States.

Contacts

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

+45 4911 2607

dklina@coloplast.com

Ellen Bjurgert

Vice President, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

Attachment

logo.png

Relateret indhold
17 apr - 
Onsdagens aktier: Coloplast faldt, men GN faldt mest
17 apr - 
FDA-påbud skærer 25 mio. dollar af toplinjen hos Colopl..
17 apr - 
Middag: Coloplast sætter sig mere end markedet efter FD..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Episode 15 - Lars Seier Christensen ser FC Porto som model for FCK

11-04-2019 15:15:13
I denne episode er finansmanden Lars Seier Christensen gæst i studiet hos Euroinvestors Lars Christensen til en snak om investeringer i sports- og fritidsindustrien med afsæt i Lars Seier Christensens nylige investering i Parken Sport & Entertainment - virksomheden bag fodboldklubben FC København.I samtalen fremhæver Lars Seier Christensen blandt andet den portugisiske fodklub FC Porto som en mode..

Aktier/tendens: Panalpina-tal kan give DSV-fokus i rolig handelsstart

17-04-2019 07:48:02
DSV kan komme i fokus onsdag, efter at schweiziske Panalpina, som den danske transportgigant er ved at overtage, fra morgenstunden har præsenteret regnskabstal, der var bedre end ventet blandt analytikerne.I årets første kvartal nåede Panalpina en omsætning på 1,49 mia. schweizerfranc, svarende til 9,8 mia. kr., hvor der blandt analytikere adspurgt af Bloomberg News var ventet en omsætning på 1,45..

Genmab-partner leverer bedre end ventet: Darzalex skuffer lidt

16-04-2019 12:58:48
Den amerikanske medicinalvirksomhed Johnson & Johnson, der samarbejder med danske Genmab omkring salg af kræftmidlet Darzalex, har leveret et bedre end ventet regnskab for første kvartal.Til gengæld ser det globale salg af Darzalex ud til at skuffe, da det i første kvartal endte på 629 mio. dollar. Til sammenligning havde Sydbanks senioranalytiker Søren Løntoft Hansen ventet et globalt salg på 660..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Coloplast B A/S 685,40 -1,7% Fald i aktiekurs
Coloplast 108,95 0,0% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. april 2019 20:23:38
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190410.2 - EUROWEB6 - 2019-04-19 20:23:38 - 2019-04-19 20:23:38 - 1 - Website: OKAY